Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data

Author:

Paules Catharine I1,Gallagher Shannon K2,Rapaka Rekha R3,Davey Richard T4,Doernberg Sarah B5,Grossberg Robert6,Hynes Noreen A7,Ponce Philip O8,Short William R9,Voell Jocelyn4,Wang Jing10,Yang Otto O11,Wolfe Cameron R12,Lye David C13,Dodd Lori E2,Benson Constance A14

Affiliation:

1. Division of Infectious Diseases, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA

2. Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA

3. University of Maryland Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA

4. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

5. Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, California, USA

6. Department of Medicine, Division of Infectious Diseases, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA

7. Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA

8. Division of Infectious Diseases, University of Texas Health San Antonio and University Health, San Antonio, Texas, USA

9. Department of Medicine, Division of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania, USA

10. Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA

11. Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA

12. Department of Medicine, Infectious Disease, Duke University Medical Center, Durham, North Carolina, USA

13. National Centre for Infectious Diseases; Tan Tock Seng Hospital; Yong Loo Lin School of Medicine; Lee Kong Chian School of Medicine; Singapore

14. Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, California, USA

Abstract

Abstract This post hoc analysis of the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1 (ACTT-1) shows a treatment effect of remdesivir (RDV) on progression to invasive mechanical ventilation (IMV) or death. Additionally, we create a risk profile that better predicts progression than baseline oxygen requirement alone. The highest risk group derives the greatest treatment effect from RDV.

Funder

NIAID

NIH

Medical Research Council

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3